Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4/6 Pathway.

Head & neck - 1 Jun 2026

Park Joo-Hwan, Ahn Hee Kyung, Kim Hye Ryun, Kim Soyeon, Park Keon-Uk, Yun Tak, Kim Hyo Jung, Lee Sang-Cheol, Cho Sang Hee, Park Sang-Gon, Keam Bhumsuk, Yun Hwan Jung

Abstract excerpt

BACKGROUND: HPV-negative HNSCC is driven by cell cycle dysregulation, including CDK4/6 activation. Abemaciclib targets this pathway and may offer therapeutic benefits. This study aimed to identify biomarkers predicting abemaciclib efficacy. METHODS: In the NGS-based TRIUMPH trial, patients with platinum-refractory HNSCC harboring CDK4/6 pathway alteration received abemaciclib, classified as "long stable disease...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminopyridines
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin D1

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Head and Neck Neoplasms

Share to Squamous Cell Carcinoma of Head and Neck

Source

Identifiers

PMID: 41527715
DOI: 10.1002/hed.70165

Genes

CDKN2A
CDK4
CCND1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploratory Biomarker Analysis of Abemaciclib in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Dysregulated CDK4/6 Pathway.PMID 41527715Read ↗

Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinomaSemantic proximity Read ↗

Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial.Semantic proximity Read ↗

CDK4/6 Inhibition Uncovers Subtype-Specific Vulnerabilities and Immune-Related Responses in Esophageal Squamous Cell CarcinomaSemantic proximity Read ↗

Dual CDK and MEK Inhibition potentiates CD8+ T cell-mediated antitumor immunity by inducing pyroptotic cell death in high-mutational head and neck cancer.Semantic proximity Read ↗

Leveraging Genomics for Head and Neck Cancer Treatment.Semantic proximity Read ↗

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristicsSemantic proximity Read ↗

Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.Semantic proximity Read ↗

Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture modelsSemantic proximity Read ↗

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclibSemantic proximity Read ↗

Mutational profiles of head and neck squamous cell carcinomas based upon human papillomavirus status in the Veterans Affairs National Precision Oncology Program.Semantic proximity Read ↗

Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.